RILZABRUTINIB FOR DUMMIES

There have been no clinically major variances during the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when used concomitantly with finerenone. A number of doses of 40 mg finerenone at the time-day-to-day experienced no clinically relevant effect on AUC or Cmax of the BCRP and OATP substrate rosuvastatin.